High impact information on Hexobendine

• Use of hexobendine to examine whether the coronary vasodilator metabolite released from guinea-pig isolated hearts is adenosine [1].
• Effects of the carboxylesterase inhibitor bis-(p-nitrophenyl)-phosphate on elimination of hexobendine [2].
• 5 It is suggested that an adenosine uptake process may exist in the trachea of the guinea-pig and that this process is inhibited by dipyridamole, hexobendine and Dilazep [3].
• Adenosine uptake by erythrocytes of man, rat and guinea-pig and its inhibition by hexobendine and dipyridamole [4].
• These blockers, viz. dilazep, hexobendine, soluflazine and ST7092, provided to be more potent in this respect at pH 9.5 than at pH 6.6, although to differing extents [5].

Biological context of Hexobendine

• 5. The results suggest that hexobendine and papaverine inhibit adenosine uptake by occupying the [H3]NBMPR high affinity binding sites [6].

Anatomical context of Hexobendine

• Of the compounds tested in this study, lidoflazine (8.2X) and hexobendine (6.3X) have the greatest selectivity for coronary endothelial cell nucleoside transporters [7].
• This difference was not altered when the degradation of hexobendine by the jejunal epithelium was blocked by physostigmine [8].

Associations of Hexobendine with other chemical compounds

• While a few drugs (midodrin, proxazole, vincamine, hexobendine, extract of ginkgo biloba, dextran and ouabain) were able to improve hemispheric CBF, only ephedrine combined with xanthines decreased CBF [9].

Analytical, diagnostic and therapeutic context of Hexobendine

• Both responses were potentiated during perfusion with hexobendine [1].

References